On December 8, 2025 (after trading hours), Nova Pneuma Incorporated (an indirect wholly-owned subsidiary of LEE'S PHARM (00950)), the company, Alexza Pharmaceuticals, Inc., and its parent company Grupo Ferrer International, S.A., entered into an asset purchase agreement. Under the agreement, the buyer agreed to acquire, and the seller agreed to sell, business-related assets of Alexza for a consideration of $15 million.

The acquired assets include all assets, properties, equipment, machinery, materials (including work-in-progress), patents and other intellectual property, technical know-how, rights, and assigned contracts related to Alexza's business.

LEE'S PHARM primarily engages in pharmaceutical development, manufacturing, and commercialization in China and international markets. The acquisition aligns with the group's strategy to expand its innovative drug delivery technology portfolio, including the *Staccato®* platform, which covers a broad range of therapeutic indications. It also supports the company's global expansion plans.

The acquisition is expected to create value for the company and its shareholders, with key investment highlights including: (a) *Staccato®* One Breath Technology®, a proprietary platform technology with broad therapeutic potential; (b) Synergies and complementarity with the company's existing product pipeline; (c) A global licensing, manufacturing, and supply agreement with UCB, a leading biopharmaceutical company in epilepsy treatment, marking a significant milestone in the company's global expansion strategy.